Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Near-infrared Fluorescence Molecular Imaging of Adalimumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Inflammatory Bowel Disease and Rheumotoid Arthritis

Next Previous
Search
Trial Profile

Near-infrared Fluorescence Molecular Imaging of Adalimumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Inflammatory Bowel Disease and Rheumotoid Arthritis

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Inflammatory bowel diseases; Rheumatoid arthritis
  • Focus Adverse reactions; Diagnostic use
  • Acronyms STRATIFY

    • Most Recent Events

    • 02 May 2023 According to ClinicalTrials.gov record, protocol has been amended to change the experimental drug from OTL38 to Adalimumab. number of arms were increased. Also the time frames of the primary endpoints has been changed.
    • 02 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
    • 02 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top